top of page
News
eGlint Wins 2026 BioTools Innovator Grand Prize, Recognizing Its Breakthrough in Rapid, Distributed Proteomics
Company awarded $250,000 Grand Prize at BioTools Innovator Capstone Competition, highlighting the potential of its ProteoNex™ biosensor platform to transform protein measurement across life science research, biomanufacturing, and clinical diagnostics. SAN DIEGO, CA — October 19, 2026 — eGlint, Inc., a biotechnology company developing next-generation rapid, distributed protein measurement technologies, announced that it has been named the 2026 BioTools Innovator Grand Prize Wi
denismalyshev
14 minutes ago4 min read


eGlint Joins Novelna-Led ARPA-H DELPHI Project to Advance Continuous Wearable Molecular Monitoring
Building on a successful proof-of-concept collaboration with Siomyx, eGlint will contribute its ProteoNex™ biosensing technology to next-generation wearable devices. LA JOLLA, Calif. — October 2026 — eGlint, a biotechnology company developing next-generation molecular biosensing technologies, today announced its participation in PULSE (Proactive Unified Longitudinal Sensing Ecosystem), a Novelna-led project supported by the Advanced Research Projects Agency for Health (ARPA-H
denismalyshev
Oct 93 min read


eGlint Named One of Four Finalists in BioTools Innovator’s 2026 Grand Prize Competition
The company will compete for the $250,000 grand prize at the BioTools Innovator Capstone in San Diego on October 14. SAN DIEGO — September 24, 2026 — eGlint, a biotechnology company developing rapid, multiplex protein analysis, has been named one of four finalists in BioTools Innovator’s 2026 Grand Prize Competition. The finalists emerged from a 30-company accelerator cohort selected from more than 500 applicants worldwide. The recognition comes as eGlint advances ProteoMix™,
denismalyshev
Sep 252 min read


eGlint Presents at BARDA Accelerator Network Showcase in Chicago
eGlint participated in the BARDA Accelerator Network Showcase in Chicago as a member of the 2026 BioTools Innovator VANGUARD cohort. CEO Robert Georgantas and founder/COO Denis Malyshev represented the company, which was among those invited to present a poster. The presentation highlighted ProteoCare™ and ProteoHome™, eGlint’s point-of-care and home-testing systems in development, and their potential applications in rapid testing for pandemic preparedness. The poster generate
denismalyshev
Sep 161 min read


eGlint Selected for the 2026 BioTools Innovator Cohort
Last week, the eGlint team participated in the 2026 Innovator Summit in San Francisco after being selected into the 2026 BioTools Innovator cohort. The invitation-only event brought together founders, executives, investors, industry leaders, strategic partners, and fellow innovators working to advance the next generation of life science and healthcare technologies. One message came through consistently throughout the week: stay relentlessly focused on solving real customer

Denis Malyshev
Jun 91 min read


bottom of page